Clinical Trials Directory

Trials / Terminated

TerminatedNCT00912899

A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

A Phase I Open Label Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Status
Terminated
Phase
Phase 1
Study type
Interventional
Enrollment
12 (actual)
Sponsor
Cougar Biotechnology, Inc. · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This is a phase 1 study to evaluate the safety and determine maximum tolerated dose, safety \& tolerability of noscapine HCl in patients with advanced multiple myeloma

Conditions

Interventions

TypeNameDescription
DRUGNoscapine HClEscalating doses given twice per day

Timeline

Start date
2007-12-01
Primary completion
2010-07-01
Completion
2010-07-01
First posted
2009-06-03
Last updated
2016-10-07

Locations

4 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00912899. Inclusion in this directory is not an endorsement.

A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma (NCT00912899) · Clinical Trials Directory